Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
Research analysts at HC Wainwright issued their FY2025 EPS estimates for Grace Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat ...
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
On Tuesday, H.C. Wainwright reaffirmed a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), maintaining a Buy rating and a $7.00 price target. Currently trading at $1.10, with a market ...
Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...
will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...
Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...
will participate in the H.C. Wainwright 3 rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. (PRNewsfoto/CARISMA Therapeutics Inc.) An audio webcast of the event ...
On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $12.00 price target for Grace Therapeutics (NASDAQ:GRCE), which currently trades at $3.45 with a market cap of $35 million. According to ...
In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...
NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results